PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. (12th June 2019) - Rogers, K.A.; Thompson, P.A.; Allan, J.N.; Coleman, M.; Sharman, J.P.; Cheson, B.D.; Izumi, R.; Frigault, M.M.; Quah, C.; Raman, R.K.; Wang, M.H.; Kipps, T.J.